Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 1
1949 1
1950 5
1951 6
1952 11
1953 8
1954 10
1955 14
1956 13
1957 19
1958 14
1959 17
1960 11
1961 9
1962 14
1963 10
1964 34
1965 12
1966 21
1967 19
1968 31
1969 52
1970 25
1971 22
1972 32
1973 36
1974 26
1975 36
1976 26
1977 38
1978 33
1979 56
1980 55
1981 62
1982 67
1983 56
1984 47
1985 73
1986 65
1987 139
1988 496
1989 1091
1990 1792
1991 2325
1992 2614
1993 2686
1994 2885
1995 2972
1996 3156
1997 3255
1998 3401
1999 3640
2000 3639
2001 3482
2002 3340
2003 3426
2004 3746
2005 3855
2006 4069
2007 4120
2008 4295
2009 4562
2010 4597
2011 4735
2012 4722
2013 4627
2014 4541
2015 4214
2016 4071
2017 3694
2018 3471
2019 3538
2020 3656
2021 3581
2022 3029
2023 2562
2024 830

Text availability

Article attribute

Article type

Publication date

Search Results

118,522 results

Results by year

Filters applied: . Clear all
Page 1
Extracorporeal membrane oxygenation-hemostatic complications.
Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, Davis AK. Murphy DA, et al. Transfus Med Rev. 2015 Apr;29(2):90-101. doi: 10.1016/j.tmrv.2014.12.001. Epub 2014 Dec 18. Transfus Med Rev. 2015. PMID: 25595476 Review.
Patients requiring ECMO are a heterogenous group of critically ill patients with cardiac and respiratory failure. Bleeding and thrombotic complications remain a leading cause of morbidity and mortality in patients on ECMO. In this review, we describe the mechanisms and man …
Patients requiring ECMO are a heterogenous group of critically ill patients with cardiac and respiratory failure. Bleeding and thrombotic …
Mechanisms of ADAMTS13 regulation.
DeYoung V, Singh K, Kretz CA. DeYoung V, et al. J Thromb Haemost. 2022 Dec;20(12):2722-2732. doi: 10.1111/jth.15873. Epub 2022 Sep 22. J Thromb Haemost. 2022. PMID: 36074019 Free PMC article. Review.
Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary thrombotic thrombocytopenic purpura, a lethal microvascular condition resulting from ADAMTS13 deficiency. Preclinical studies have also demonstrated its efficacy in tre …
Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary thrombotic thrombocytopenic purp …
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.
Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Zheng XL, et al. J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914582 Free PMC article.
BACKGROUND: Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly. OBJECTIVE: The evidence-based guidelines of the International So …
BACKGROUND: Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the …
Vaccine-induced immune thrombotic thrombocytopenia.
Cines DB, Greinacher A. Cines DB, et al. Blood. 2023 Apr 6;141(14):1659-1665. doi: 10.1182/blood.2022017696. Blood. 2023. PMID: 36669155 Free PMC article.
Within the first months of the COVID-19 vaccination campaign, previously healthy recipients who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and thrombocytopenia typically after adenoviral vector-based vaccination were identified. ...We update …
Within the first months of the COVID-19 vaccination campaign, previously healthy recipients who developed severe thrombosis (often ce …
Platelet-activating anti-PF4 disorders: An overview.
Warkentin TE. Warkentin TE. Semin Hematol. 2022 Apr;59(2):59-71. doi: 10.1053/j.seminhematol.2022.02.005. Epub 2022 Feb 20. Semin Hematol. 2022. PMID: 35512902 Free article. Review.
Most recently, a novel fourth anti-PF4 disorder, vaccine-induced immune thrombotic thrombocytopenia (VITT), was identified as an ultrarare complication of adenovirus vector vaccines. VITT is characterized by thrombocytopenia, disseminated intravascular coagulation, a high …
Most recently, a novel fourth anti-PF4 disorder, vaccine-induced immune thrombotic thrombocytopenia (VITT), was identified as an ultr …
Treatment of drug-induced immune thrombocytopenias.
Marini I, Uzun G, Jamal K, Bakchoul T. Marini I, et al. Haematologica. 2022 Jun 1;107(6):1264-1277. doi: 10.3324/haematol.2021.279484. Haematologica. 2022. PMID: 35642486 Free PMC article. Review.
Immune-mediated thrombocytopenia, on the other hand, involves the formation of antibodies that react to platelet-specific glycoprotein complexes, as in classic drug-induced immune thrombocytopenia (DITP), or to platelet factor 4, as in heparin-induced thrombocytopenia (HIT) and v …
Immune-mediated thrombocytopenia, on the other hand, involves the formation of antibodies that react to platelet-specific glycoprotein compl …
Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM. Tsai HM. Am J Med. 2019 Sep;132(9):1032-1037. doi: 10.1016/j.amjmed.2019.03.009. Epub 2019 Mar 28. Am J Med. 2019. PMID: 30928346 Review.
The discovery of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats member-13) and its deficiency in patients with thrombotic thrombocytopenic purpura, due to inhibitory autoantibodies or genetic mutations, provides a mechanistic s …
The discovery of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats member-13) and its deficiency in patients wi …
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gäckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Mühlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Müller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tölle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schönermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Völker LA, et al. J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696206 Free article.
BACKGROUND: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety. ...
BACKGROUND: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thromb …
Spanish registry of thrombotic thrombocytopenic purpura (REPTT): Data evidence and new developments.
Mingot-Castellano ME, Izquierdo CP, Del Rio Garma J. Mingot-Castellano ME, et al. Transfus Apher Sci. 2023 Jun;62(3):103725. doi: 10.1016/j.transci.2023.103725. Epub 2023 May 11. Transfus Apher Sci. 2023. PMID: 37202322 Review.
Immuno Thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially fatal disorder characterized by systemic microvascular thrombosis because of a severe deficiency of ADAMTS13. ...
Immuno Thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially fatal disorder characterized by systemic mi …
ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
Sui J, Zheng L, Zheng XL. Sui J, et al. Arch Pathol Lab Med. 2023 Aug 1;147(8):974-979. doi: 10.5858/arpa.2022-0050-RA. Arch Pathol Lab Med. 2023. PMID: 36223210 Free PMC article. Review.
CONTEXT.-: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but potentially fatal blood disorder resulting from acquired deficiency of plasma ADAMTS13, a metalloprotease that cleaves endothelium-derived ultralarge von Willebrand factor. Standard of …
CONTEXT.-: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but potentially fatal blood disorder resulting f …
118,522 results
You have reached the last available page of results. Please see the User Guide for more information.